Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)

Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX®▼ (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.

Click on this link for more information.